THYROTROPIN RECEPTOR ANTIBODY SERUM
General Information
HLAB/HOL Code: THYRR
UPHSM LIS Test #: 027794
Schedule:
Testing Time: 1-3 Days
Testing Lab: Labcorp
UPHSM LIS Test #: 027794
Schedule:
Testing Time: 1-3 Days
Testing Lab: Labcorp
Specimen Info
Only 1 specimen type required, unless otherwise specified
Volume: 1.0 mL
Temperature: Frozen
Tube Type: Serum
Collection Info:
Minimum Volume: 0.7 mL (Note: This volume does not allow for repeat testing.)
Container: Gel-barrier tube (preferred) or red-top tube
Temperature: Frozen
Tube Type: Serum
Collection Info:
Minimum Volume: 0.7 mL (Note: This volume does not allow for repeat testing.)
Container: Gel-barrier tube (preferred) or red-top tube
Specimen Acceptability
Causes for Rejection
Citrate plasma specimen; samples collected in heparin or samples from patients on heparin therapy; lipemic or hemolyzed serum samples; improper labeling
Citrate plasma specimen; samples collected in heparin or samples from patients on heparin therapy; lipemic or hemolyzed serum samples; improper labeling
Methods
Electrochemiluminescence immunoassay (ECLIA)
Clinical Utilities
Diagnosis of hyperthyroidism and Graves' disease.
Additional Information:
Thyrotropin-receptor antibody is an autoantibody to the thyroid cell receptor for thyroid-stimulating hormone. It can be demonstrated in 90% of patients with Graves' disease, and is the cause of the hyperthyroidism of that condition. The characterization of TRA resolved much confusion about long-acting thyroid stimulator (LATS) and LATS protector, which are both, in fact, thyroid-stimulating autoantibodies which simply behaved differently in animal test systems. These antibodies are present in 50% of euthyroid Graves' disease as well as hyperthyroid patients. They play a major role in the pathogenesis of Graves' disease. Detection of these antibodies is useful in prediction of neonatal hyperthyroidism and prediction of relapse of hyperthyroidism.
Additional Information:
Thyrotropin-receptor antibody is an autoantibody to the thyroid cell receptor for thyroid-stimulating hormone. It can be demonstrated in 90% of patients with Graves' disease, and is the cause of the hyperthyroidism of that condition. The characterization of TRA resolved much confusion about long-acting thyroid stimulator (LATS) and LATS protector, which are both, in fact, thyroid-stimulating autoantibodies which simply behaved differently in animal test systems. These antibodies are present in 50% of euthyroid Graves' disease as well as hyperthyroid patients. They play a major role in the pathogenesis of Graves' disease. Detection of these antibodies is useful in prediction of neonatal hyperthyroidism and prediction of relapse of hyperthyroidism.
CPT Codes
83520
* The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding
is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
